Search
Cycloguanil
go.drugbank.com/drugs/DB14763ApprovedCycloguanil is the active metabolite of [proguanil].
Categories: Heterocyclic Compounds, 1-RingEtrasimod
go.drugbank.com/drugs/DB14766ApprovedInvestigationalEtrasimod is a synthetic next-generation selective Sphingosine 1-phosphate (S1P) receptor modulator that targets the S1P<sub>1,4,5</sub> with no detectable activity on S1P<sub>2</sub> and S1P<sub>3</sub … 2-mg daily dose regimen of etrasimod, with a 32% and 26% remission rate observed in UC 52 and UC 12 trials respectively.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 2-RingGDC-0425
go.drugbank.com/drugs/DB14791InvestigationalGDC-0425 is under investigation in clinical trial NCT01359696 (A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory
Categories: Heterocyclic Compounds, 1-RingPiflufolastat F 18
go.drugbank.com/drugs/DB14805ApprovedInvestigationalProstate-specific membrane antigen (PSMA) is a transmembrane glycoprotein expressed in many tissues that plays a role in folate uptake and neurotransmitter release - it is expressed in the prostate at … [A235169] As such, it has become a desirable target for PET imaging of prostate cancer tissues.
Categories: Heterocyclic Compounds, 1-RingSynonyms: DCFPyL F-18, [F-18] DCFPyLObefazimod
go.drugbank.com/drugs/DB14828InvestigationalABX-464 is under investigation in clinical trial NCT03905109 (Safety Evaluation of ABX464 in Patients With Moderate to Severe Active Crohn's Disease).
Categories: Heterocyclic Compounds, 2-RingUproleselan
go.drugbank.com/drugs/DB14829InvestigationalUproleselan is a novel, specific E-Selectin antagonist under investigation in clinical trial NCT02306291 (Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy
Categories: E-Selectin, antagonists & inhibitorsEnsartinib
go.drugbank.com/drugs/DB14860ApprovedInvestigational[A273963, A273958] Ensartinib is a first-line treatment for anaplastic lymphoma kinase (ALK)-mutated non-small cell lung cancer (NSCLC). … Non-small cell lung cancer (NSCLC) is one of the most frequent subtypes of lung cancers and encompasses a variety of different lung cancers, with notable ones being adenocarcinoma, squamous cell carcinoma
Categories: P-glycoprotein substrates, Heterocyclic Compounds, 1-RingCefiderocol
go.drugbank.com/drugs/DB14879ApprovedInvestigationalCefiderocol is a cephalosporin antibacterial drug and exerts a mechanism of action similar to other β-lactam antibiotics. … [A189057] It represents a significant addition to antibacterial treatment option as it has proven to be effective *in vitro* against multidrug resistant strains including extended spectrum β-lactamase
Categories: Heterocyclic Compounds, 2-Ring, Compounds used in a research, industrial, or household settingRitlecitinib
go.drugbank.com/drugs/DB14924ApprovedInvestigational[L48181] Ritlecitinib is administered orally and is the first member of its class. … Ritlecitinib (PF-06651600) is a highly selective inhibitor of Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsSynonyms: 2-propen-1-one, 1-((2S,5R)-2-methyl-5-(7H-pyrrolo(2,3-D)pyrimidin-4-ylamino)-1-piperidinyl)-Pyrotinib
go.drugbank.com/drugs/DB14993InvestigationalPyrotinib is under investigation in clinical trial NCT03756064 (Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer).
Categories: Heterocyclic Compounds, 2-Ring